TY - JOUR
T1 - Estandarización y validación de una prueba molecular RT-lamp in house para el diagnóstico de SARS-CoV-2
AU - Escalante-Maldonado, Oscar
AU - Vidal-Anzardo, Margot
AU - Donaires, Fernando
AU - Solis-Sanchez, Gilmer
AU - Gallesi, Italo
AU - Pampa-Espinoza, Luis
AU - Huaringa, Maribel
AU - Rojas-Serrano, Nancy
AU - García, Coralith
AU - Angles-Yanqui, Eddie
AU - Gavilán, Ronnie Gustavo
AU - Durães-Carvalho, Ricardo
AU - Mendez-Rico, Jairo
AU - Cabezas, César
AU - Marques-Simas, Paulo Vitor
N1 - Publisher Copyright:
© 2021, Instituto Nacional de Salud. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Objectives: To standardize and validate an in-house RT-LAMP test for the detection of SARS-CoV-2, based on laboratory and field assays using samples from COVID-19 suspected patients. Materials and methods: An in-house SARS-CoV-2 RT-LAMP molecular test was standardized, establishing the detection limit with Vero cells of isolated Peruvian strains of SARS-CoV-2, and the robustness to various concentrations of primers. The laboratory validation was performed with 384 nasal and pharyngeal swab samples (UFH) obtained between March and July 2020. The field validation was performed with 383 UFH obtained from COVID-19 suspected symptomatic cases. All samples were tested by RT-LAMP and RT-qPCR. The RT-qPCR was considered as the reference standard test. The concordance measures and diagnostic performance were calculated. Results: The detection limit was consistent in cases with Ct <30 in both tests, showing efficiency to detect up to 1000 copies/μL of the target gene. Robustness was evidenced with half of the primer concentrations and 20 μL of final volume. Absence of amplification was identified for other HCoVs. Concordance showed a kappa index of 0.88 (95% CI: 0.83-0.93) and 0.89 (95% CI: 0.84-0.94) in laboratory and field settings, respectively. The sensitivity value in the laboratory was 87.4% (95% CI: 80.8-92.4) and 88.1% in the field (95% CI: 81.6-92.9). The specificity value in both settings was 98.8% (95% CI: 96.4-99.7). Conclusions: The in-house SARS-CoV-2 RT-LAMP test was successfully validated based on its adequate robustness, no cross-reactions, good concordance, and diagnostic performance compared to RT-qPCR.
AB - Objectives: To standardize and validate an in-house RT-LAMP test for the detection of SARS-CoV-2, based on laboratory and field assays using samples from COVID-19 suspected patients. Materials and methods: An in-house SARS-CoV-2 RT-LAMP molecular test was standardized, establishing the detection limit with Vero cells of isolated Peruvian strains of SARS-CoV-2, and the robustness to various concentrations of primers. The laboratory validation was performed with 384 nasal and pharyngeal swab samples (UFH) obtained between March and July 2020. The field validation was performed with 383 UFH obtained from COVID-19 suspected symptomatic cases. All samples were tested by RT-LAMP and RT-qPCR. The RT-qPCR was considered as the reference standard test. The concordance measures and diagnostic performance were calculated. Results: The detection limit was consistent in cases with Ct <30 in both tests, showing efficiency to detect up to 1000 copies/μL of the target gene. Robustness was evidenced with half of the primer concentrations and 20 μL of final volume. Absence of amplification was identified for other HCoVs. Concordance showed a kappa index of 0.88 (95% CI: 0.83-0.93) and 0.89 (95% CI: 0.84-0.94) in laboratory and field settings, respectively. The sensitivity value in the laboratory was 87.4% (95% CI: 80.8-92.4) and 88.1% in the field (95% CI: 81.6-92.9). The specificity value in both settings was 98.8% (95% CI: 96.4-99.7). Conclusions: The in-house SARS-CoV-2 RT-LAMP test was successfully validated based on its adequate robustness, no cross-reactions, good concordance, and diagnostic performance compared to RT-qPCR.
KW - COVID-19
KW - Cross reactions
KW - Diagnosis
KW - Molecular diagnostic techniques
KW - Polymerase chain reaction
KW - Predictive value of tests
KW - ROC curve
KW - Sensitivity and specificity
KW - Validation study
UR - http://www.scopus.com/inward/record.url?scp=85110199199&partnerID=8YFLogxK
U2 - 10.17843/rpmesp.2021.381.7154
DO - 10.17843/rpmesp.2021.381.7154
M3 - Artículo
C2 - 34190927
AN - SCOPUS:85110199199
SN - 1726-4634
VL - 38
SP - 7
EP - 16
JO - Revista Peruana de Medicina Experimental y Salud Publica
JF - Revista Peruana de Medicina Experimental y Salud Publica
IS - 1
ER -